Analysts Viewpoint Examining the Potential Price Growth of ARS Pharmaceuticals Inc (SPRY) ARS Pharmaceuticals Inc’s recently made public that its Chief Commercial Officer Karas Eric unloaded Company’s shares for reported $0.25 million
Stock Earnings 0 analysts rank SPRY stock as an Overweight Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. ARS Pharmaceuticals